Dr. Paulson on the Utility of Liquid Biopsies Versus Tissue Biopsies

Video

R. Steven Paulson, MD, discusses the utility of liquid biopsies versus tissue biopsies.

R. Steven Paulson, MD, physician, Texas Oncology, discusses the utility of liquid biopsies versus tissue biopsies.

Although tissue biopsy remains the gold standard in oncology, there may not be enough available tissue to perform a biopsy, explains Paulson. In these cases, a patient may need to undergo an invasive procedure to retrieve more tissue for testing.

Alternatively, a liquid biopsy may alleviate the need for an invasive procedure since it only requires a blood draw, says Paulson. A positive result with a liquid biopsy is relatively reliable; however, a negative test result should not be considered definitive.

Additionally, the turn-around time for a liquid biopsy is faster than a tissue biopsy. Therefore, if a liquid biopsy is positive, patients can begin targeted therapy earlier. However, the interpretation of liquid biopsies requires some standardization, concludes Paulson.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute